Altamira Therapeutics Ltd. · OTC:CYTOF

Altamira Therapeutics — Auris Medical Holding — Corporate Update (October 2016)

25 slides from Altamira Therapeutics's corporate update, Oct 11, 2016

  1. Slide 1: Keyzilen Program Update

    NASDAQ: EARS Keyzilen TM Program Update October 11, 2016

  2. Slide 2: Forward-looking Statements

    1 Forward - looking Statements NASDAQ: EARS This presentation and the accompanying oral commentary contain “forward - looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying o r

  3. Slide 3: Keyzilen Development Plan Update

    Keyzilen™ Development Plan Update (@ Auris Medical Cochlear therapies wor aurismedical.com

  4. Slide 4: Today's Agenda

    3 Today’s Agenda NASDAQ: EARS • TACTT2 trial: Additional results and learnings • TACTT3 trial: Protocol amendment • Planned discussions with FDA regarding US regulatory pathway

  5. Slide 5: TACTT2 Trial Design Overview

    4 TACTT2 Trial Design Overview • Acute peripheral tinnitus following traumatic cochlear insult or otitis media – Traumatic cochlear insult includes acute noise trauma, barotrauma, surgery trauma • Up to 3 months from onset • Conducted primarily in North America Screening Treatment Follow - Up SV │ D

  6. Slide 6: TACTT2 Trial – Baseline and Demographics

    TACTT2 Trial – Baseline and Demographics 5 Co - primary endpoints, measured from baseline to Day 84: • Change in subjective tinnitus loudness (TLQ; 0 - 10) – Baseline values: 6.44 points for Keyzilen , 6.47 points for placebo • Change in tinnitus burden (TFI; 0 - 100) – Baseline values: 52.4 points

  7. Slide 7: Co-Primary Efficacy Endpoints

    Co - Primary Efficacy Endpoints 6 p=0.321 p=0.565

  8. Slide 8: TACTT2 Trial – Outcome Analysis

    7 TACTT2 Trial – Outcome Analysis NASDAQ: EARS Two principal sources for disappointing outcome: • Trial design – High frequency (daily) of tinnitus loudness ratings over extended time period – TLQ showed lower sensitivity to change than the TFI • Trial administration – High variability in outcomes b

  9. Slide 9: Subgroup – Otitis Media-Related Tinnitus

    Subgroup – Otitis Media - Related Tinnitus 8 • Clinically meaningful and statistically significant TFI result s in subgroup with otitis media - related tinnitus • ∆ TFI ≥ 13 defined as clinically meaningful by TFI developers • Pre - specified subgroup p=0.148 p=0.048 p=0.565

  10. Slide 10: Subgroup – Severe or Extreme Tinnitus

    Subgroup – Severe or Extreme Tinnitus 9 • Post - hoc analysis showing trend for improvement in subgroup with severe or extreme tinnitus at baseline • Based on self - rated global severity and TFI definition • Clinically meaningful improvement in TFI for severe or extreme tinnnitus subgroup p=0.565 p

  11. Slide 11: TACTT2 Trial – Safety Outcomes

    10 TACTT2 Trial – Safety Outcomes NASDAQ: EARS • Data show that Keyzilen was well tolerated and confirm favorable safety profile • Low incidence of clinically meaningful hearing deterioration – Primary safety endpoint did not show a significant difference between treatment groups (p=0.82) • No drug

  12. Slide 12: TACTT2 – Summary

    11 TACTT2 – Summary NASDAQ: EARS • TACTT2 failure to confirm efficacy of Keyzilen in overall trial population clearly disappointing • Clinically meaningful reductions in tinnitus burden in relevant subgroups very encouraging • New knowledge gained from TACTT2 allows appropriate adjustments to TACTT3

  13. Slide 13: TACTT3 Development Plan Update

    TACTT3 Development Plan Update (@ Auris Medical Cochlear therapies wor aurismedical.com

  14. Slide 14: Original TACTT3 Trial Design / Enrollment

    13 Original TACTT3 Trial Design / Enrollment NASDAQ: EARS TACTT3 – A TACTT3 – B Patients Acute inner ear tinnitus, within 3 months from onset Post - acute inner ear tinnitus , 3 - 6 months from onset Dosing Single treatment cycle of three intratympanic injections over 3 - 5 days, randomized 3:2 to 0

  15. Slide 15: TACTT3 Trial – Protocol Amendments

    14 TACTT3 Trial – Protocol Amendments NASDAQ: EARS 1. TFI elevated from key secondary endpoint to alternate primary efficacy endpoint – TFI has ability to directly measure the clinically relevant tinnitus burden – TFI showed higher sensitivity than TLQ in TACTT2 – Study can be considered successful

  16. Slide 16: TACTT3 Trial – Statistical Powering

    15 TACTT3 Trial – Statistical Powering NASDAQ: EARS Amended TACTT3 trial, including additional patients, to have statistical power of: • 87% to show significance for the TFI on at least one of the three patient populations: overall, otitis media tinnitus, severe tinnitus – Assumptions:  Standard de

  17. Slide 17: TACTT3 Trial – Summary

    16 TACTT3 Trial – Summary NASDAQ: EARS • Favorable differences in patient demographics and trial conduct compared to TACTT2 • Measures implemented under amendment will enhance assay sensitivity and shift focus to the TFI • Increased likelihood of positive trial that successfully detects true treatme

  18. Slide 18: Keyzilen Regulatory Update

    Keyzilen Regulatory Update wor aurismedical.com ”

  19. Slide 19: Keyzilen Regulatory Update

    18 Keyzilen Regulatory Update • TACTT3 protocol amendment to be submitted to regulatory agencies and ethics committees in Europe • Anticipate approvals around the end of 2016 • Plan to resume trial enrollment in January 2017 • Expect top - line results from expanded TACTT3 trial in early 2018 NASDAQ

  20. Slide 20: Keyzilen Regulatory Update

    19 Keyzilen Regulatory Update • Type C meeting with FDA scheduled for early December • Written responses • Plan to seek feedback on: – TACTT2 outcomes – TACTT3 protocol modifications – US regulatory path forward NASDAQ: EARS

  21. Slide 21: Corporate Overview

    Corporate Overview wor aurismedical.com

  22. Slide 22: AM-111 for Acute Inner Ear Hearing Loss

    21 AM - 111 for Acute Inner Ear Hearing Loss • Potential to become first specific therapeutic for acute inner ear hearing loss • Launched HEALOS in November 2015: Over 50% of patients enrolled • Launched ASSENT in June 2016: Trial ramping up • Top - line results expected in second half of 2017 • Obj

  23. Slide 23: Keyzilen Program Update

    22 Keyzilen Program Update • Positive signals in three previous randomized and controlled trials • Corroborated positive results in two specific subgroups in TACTT2 • TACTT3 provides solid and timely opportunity to apply learnings from TACTT2 • TACTT3 protocol amendments increase probability of succ

  24. Slide 24: Questions & Answers

    Questions & Answers wor aurismedical.com

  25. Slide 25: Take care of your ears!

    Take care of your ears! wor aurismedical.com

Auris Medical Holding — Corporate Update (October 2016) on 6ix